Literature DB >> 7674256

Health related utility measurement: an introduction.

C Bakker1, S van der Linden.   

Abstract

Utility measures of health related quality of life are preference values that patients attach to their overall health status. In clinical trials, utility measures summarize both positive and negative effects of an intervention into one value between 0 (equal to death) and 1 (equal to perfect health). These measures allow for comparison of patient outcomes of different diseases, and for comparison between various health care interventions. There are 2 different approaches to utility measurement. The first is to classify patients into categories based on their responses to questions about their functional status, as for instance the Quality of Well-Being Questionnaire and the European Quality of Life Measure (EUROQOL). The 2nd approach is to ask patients to assign a single rating to their overall health by means of rating scale, standard gamble, time tradeoff, or willingness to pay. The Quality Adjusted Life Year (QALY) outcome measure includes both effects in terms of quality of quantity of life. Utilities are used as weights to adjust life years for the quality of life in order to calculate QALY. Both QALY and utilities are useful in decision making regarding appropriate procedures for groups of patients.

Entities:  

Mesh:

Year:  1995        PMID: 7674256

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  10 in total

Review 1.  Health-related quality-of-life measurement in hypertension. A review of randomised controlled drug trials.

Authors:  I Côté; J P Grégoire; J Moisan
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

2.  Utilities associated with diabetic retinopathy: results from a Canadian sample.

Authors:  S Sharma; A Oliver-Fernandez; J Bakal; H Hollands; G C Brown; M M Brown
Journal:  Br J Ophthalmol       Date:  2003-03       Impact factor: 4.638

3.  Variables related to utility in patients with ankylosing spondylitis.

Authors:  Rafael Ariza-Ariza; Blanca Hernández-Cruz; Gloria López-Antequera; Federico Navarro-Sarabia
Journal:  Clin Rheumatol       Date:  2008-09-30       Impact factor: 2.980

Review 4.  Quality of life in children and adolescents with cystic fibrosis: implications for optimizing treatments and clinical trial design.

Authors:  Janice Abbott; Louise Gee
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

5.  Changes in pulmonary function and patient-reported outcomes during COVID-19 recovery: a longitudinal, prospective cohort study.

Authors:  Aditi S Shah; Min Hyung Ryu; Cameron J Hague; Darra T Murphy; James C Johnston; Christopher J Ryerson; Christopher Carlsten; Alyson W Wong
Journal:  ERJ Open Res       Date:  2021-09-13

6.  Impact of Cystic Fibrosis Transmembrane Conductance Regulator Therapy on Chronic Rhinosinusitis and Health Status: Deep Learning CT Analysis and Patient-reported Outcomes.

Authors:  Daniel M Beswick; Stephen M Humphries; Connor D Balkissoon; Matthew Strand; Eszter K Vladar; David A Lynch; Jennifer L Taylor-Cousar
Journal:  Ann Am Thorac Soc       Date:  2022-01

7.  Clinical factors associated with lower health scores in COVID-19-related persistent olfactory dysfunction.

Authors:  Mena Said; Thanh Luong; Sophie S Jang; Morgan E Davis; Adam S DeConde; Carol H Yan
Journal:  Int Forum Allergy Rhinol       Date:  2022-01-31       Impact factor: 5.426

8.  Impact of COVID-19 versus chronic rhinosinusitis/rhinitis associated olfactory dysfunction on health utility and quality of life.

Authors:  Thanh Luong; Sophie S Jang; Mena Said; Adam S DeConde; Carol H Yan
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-09-24

9.  Disparities between Ophthalmologists and Patients in Estimating Quality of Life Associated with Diabetic Retinopathy.

Authors:  Xiaofeng Zhu; Qian Sun; Haidong Zou; Xun Xu; Xi Zhang
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

10.  EQ-5D-3L Decrements by Diabetes Complications and Comorbidities in China.

Authors:  Yichen Zhang; Jing Wu; Yingyao Chen; Lizheng Shi
Journal:  Diabetes Ther       Date:  2020-03-09       Impact factor: 2.945

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.